Canbridge Pharmaceuticals Inc. (MF1)

Overview

CANbridge Pharmaceuticals Inc. is a biopharmaceutical pioneer focused on developing, researching, and bringing to market innovative therapies geared towards the treatment of rare diseases and cancer. Established in 2012 and based in Suzhou, China, the company aims to address the unmet medical needs in these challenging health areas on a global scale. Through its robust research and development strategies, CANbridge strives to offer novel therapeutic options that can significantly impact patients' lives worldwide, enhancing their quality of life and offering hope for a healthier future.

Products and Services

• Hunterase

  An enzyme replacement therapy designed specifically for patients suffering from Hunter syndrome, Hunterase represents a critical advancement in treating this rare genetic disorder, offering hopes of managing its symptoms more effectively.

• NERLYNX (Neratinib)

  A highly potent irreversible tyrosine kinase inhibitor aimed at treating HER2-positive breast cancer, NERLYNX demonstrates CANbridge's commitment to oncology, offering new hope for patients with this aggressive form of breast cancer.

• Caphosol Mouth Rinse

  Developed for the temporary and persistent dryness of the mouth and throat, Caphosol Mouth Rinse addresses the needs of patients suffering from xerostomia, enhancing their comfort and quality of life.

• CAN008

  A glycosylation fusion protein that curtails the interaction between the CD95 receptor and its ligand CD95L by binding to CD95L. CAN008 opens new avenues in the research and potential treatment of various diseases.

• CAN108

  This orally administered small molecule ASBT inhibitor underscores CANbridge's dedication to innovative gastrointestinal treatment options, expanding its therapeutic reach.

• CAN106

  A recombinant human monoclonal antibody that specifically targets and neutralizes C5 in the complement system, CAN106 showcases the company's efforts in addressing autoimmune diseases through advanced biologics.

• CAN103, CAN104

  Both part of the company's enzyme replacement therapy (ERT) portfolio, these recombinant human enzymes are at the forefront of treating specific rare diseases, representing a leap forward in ERT development.

• CAN107

  A fibroblast growth factor 23 (FGF23) blocking antibody, CAN107 epitomizes CANbridge's venture into innovative treatments for disorders associated with abnormal phosphate metabolism.

• CAN105

  A bispecific antibody highlighting the company's foray into advanced biotechnology, offering potential new therapies for yet-untouched diseases.

• CAN201, CAN202

  Both gene therapy programs utilizing the cutting-edge adeno-associated virus (AAV) sL65 capsid technology, these initiatives represent CANbridge's significant investment in gene therapy as a frontier for curing rare genetic disorders.